about
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic AdenocarcinomaSerum CA19-9 in patients with solid pancreatic mass.Intensity of follow-up after pancreatic cancer resectionInherited predisposition to pancreatic cancer.Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Diagnostic and prognostic tumor markers in the gastrointestinal tract.Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis.Diagnostic approaches for cholangiocarcinoma.Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients.Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.Advances in biomarker research for pancreatic cancer.Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.Identifying molecular markers for the early detection of pancreatic neoplasia.Multimodality treatment of recurrent pancreatic cancer: Mith or reality?Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinomaDetection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probesThe clinical significance of autoantibodies in gastrointestinal malignancies: an overview.Pancreatic cancer screeningValue of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapyThe clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases.Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancerNormalization of Elevated CA 19-9 Level after Treatment in a Patient with the Nodular Bronchiectatic Form of Mycobacterium abscessus Lung Disease.High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer.Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.Preoperative serum levels of insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients.Current treatment options for pancreatic carcinoma.Molecular pathology of pancreatic cancer: from bench-to-bedside translation.Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures.Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.Pancreatic Cancer and Gastroenterology: A Review.The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases.Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC.Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review.A new cause for CA19.9 elevation: heavy tea consumption.[Chronic pancreatitis or pancreatic malignancy: clinical and radiological differential diagnosis of pancreas head space-occupying mass].Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis.Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
P2860
Q26744298-0A554634-9911-4C22-BAFD-FAED493E31E3Q33596555-1D99415A-4C42-404A-A9C0-41562C0D521CQ33791048-5B545465-F4B1-468C-A4DD-DA8ED2413529Q33931174-3CE088DB-E3CE-4F14-8368-8429B6B10EA2Q34275247-B32E43DC-683A-4864-B0A3-FB81A14A0692Q34277292-80AA177D-9563-4A3B-B390-23B759A236E4Q34547888-FBC617A0-0A97-435F-9242-1DD6A9F35D4CQ34594430-ED3B3D18-F51D-4715-BF81-77FEC94CFEA7Q34600819-B0812A71-824B-4C66-986A-F4675F61C8F9Q35012088-163628C9-F89F-4767-86B8-07D8A4A0421BQ35160217-E4FE7E48-91A6-4F84-83DC-13792316DECFQ36126609-7189C449-B9F6-466C-AE39-375FD273B07CQ36213547-B5672E5E-A0D3-47F1-AD83-FEB0D9CF1E6DQ36328508-31C7DDD6-3FB7-4ACB-BCF0-79A3EAD480ADQ36369834-6443505E-51A3-41E0-96CB-3D191D0CBC49Q36385644-9D8DA150-34AE-45F5-9852-A1447261BFD0Q36616092-CA4E5627-D0DD-41AD-BC8B-03DAAA684B5EQ36764924-AFF93BF4-FC24-4548-A550-6F0016EE3638Q36896536-68AE98DF-127F-4BCC-81F8-7F54CD5177D9Q36927697-D90BF9BB-0C4B-4866-B101-8454358AE14FQ36937026-0F4F6408-824C-4A1B-A1D0-6977C0911DC0Q37079045-709E7391-19B8-4F56-80D6-A3E70DD61A28Q37090049-DA49312A-F9EA-4C1F-B7FB-52BCADA88DB5Q37118841-A359D749-7D8D-4C84-ACF0-C339AC17D3F5Q37347327-6D3F1573-2511-4BE3-ABC3-03E7506EBE77Q37376572-FBF0C4EB-801C-4256-97D3-A44D3C77B1ADQ37582071-3F7724E3-8C0E-4D54-AF86-5F4021924717Q37706864-BD4BB8B0-1A84-4B05-9B77-6773B0CEC4E8Q37864970-8CEB9936-921B-4178-BAAE-9473484B745BQ37998096-AD110D72-370B-46B3-BCFD-DA0E972F200BQ38434946-3CF5E183-9C9A-4C32-A22E-43CB8CE51A16Q38680000-4CBDF55D-154A-4F19-B7D6-B24F0C007182Q38992036-D7FF9C64-0E05-414D-9BB6-FA962AFF92D8Q39448761-C7945D26-A622-4E1A-B1AF-9A768132AC03Q41489412-F80E05D8-E659-4AA8-B4A6-3ECAE8972186Q42181162-CAB8E1E6-FB66-4839-84C2-84F230FD4000Q43005662-EDE19238-9796-4022-B16E-1593E9720A81Q44510206-40022863-6068-4DB7-84CF-306EF8B65268Q47177056-2DC6AB8C-EFA2-4545-8DC9-4DAB3BCB966CQ54944542-7DCC838F-B335-4F9A-99F8-EEAD10CE2D67
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Role of tumour markers, cytogenetics.
@ast
Role of tumour markers, cytogenetics.
@en
type
label
Role of tumour markers, cytogenetics.
@ast
Role of tumour markers, cytogenetics.
@en
prefLabel
Role of tumour markers, cytogenetics.
@ast
Role of tumour markers, cytogenetics.
@en
P356
P1433
P1476
Role of tumour markers, cytogenetics.
@en
P2093
P304
P356
10.1023/A:1008386130283
P478
10 Suppl 4
P577
1999-01-01T00:00:00Z